USA-based biotech InduPro has closed a $77 million series B financing and dosed the first patient in a Phase I study of IDP-001, its lead cancer candidate, giving the Seattle and Cambridge, Massachusetts firm the means to generate early clinical data on a bispecific antibody-drug conjugate (ADC) designed around the spatial arrangement of proteins on tumor cells.
The round was led by The Column Group, with existing backers Vida Ventures, MRL Ventures Fund, the therapeutics venture arm of US pharma major Merck & Co (NYSE: MRK), Emerson Collective, advised by Yosemite, and Euclidean Capital taking part. New investors include Solasta Ventures, French drugmaker Sanofi (Euronext: SAN) and US pharma major Eli Lilly (NYSE: LLY).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK